$WHWK News

Whitehawk Therapeutics Files Prospectus For Resale Of 22,321,887 Shares Of Common Stock

Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCO

Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting

Whitehawk Therapeutics Enters PIPE Financing With Expected Gross Proceeds Of ~$87.5M From Sale Of 4,330,866 Shares At $3.92 Per Share And Warrants To Purchase 17,991,021 Shares At $3.9199 Per Warrant

Whitehawk Therapeutics Q1 EPS $(0.32) Misses $(0.09) Estimate

Reported Sunday, Whitehawk Therapeutics Presents Preclinical Data For HWK-007, HWK-016 And HWK-206 Next-Generation ADC Portfolio At AACR 2026, Showing Tumor Regressions At Low Single-Digit Mg/Kg Doses

Whitehawk Therapeutics shares are trading higher after Citizens initiated its coverage on the stock with a Market Outperform rating and announced a price target of $8.

Whitehawk Therapeutics shares are trading higher after Citizens initiated its coverage on the stock with a Market Outperform rating and announced a price target of $8.

Citizens Initiates Coverage On Whitehawk Therapeutics with Market Outperform Rating, Announces Price Target of $8

Whitehawk Therapeutics Presents Three Posters From Real-World Analysis Supporting Therapeutic Potential Of Targeting Mucin 16 With Next-Gen ADC For Treatment Of Ovarian And Endometrial Cancers At SGO 2026 Annual Meeting

Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Whitehawk Therapeutics Q4 EPS $(0.34) Misses $(0.13) Estimate

Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027

Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth

Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016

Whitehawk Therapeutics Announces FDA Has Cleared Investigational New Drug Application For HWK-007

Jones Trading Initiates Coverage On Whitehawk Therapeutics with Buy Rating, Announces Price Target of $7